XORTX Therapeutics Stock (NASDAQ:XRTX)


OwnershipFinancialsChart

Previous Close

$1.14

52W Range

$1.09 - $7.00

50D Avg

$1.40

200D Avg

$2.18

Market Cap

$3.93M

Avg Vol (3M)

$53.98K

Beta

-0.21

Div Yield

-

XRTX Company Profile


XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

2

IPO Date

Sep 23, 2021

Website

XRTX Performance


XRTX Financial Summary


Dec 22Dec 21Dec 20
Revenue---
Operating Income$-10.69M$-4.14M$-1.30M
Net Income$-6.99M$-1.30M$-1.28M
EBITDA$-10.63M$-4.12M$-1.28M
Basic EPS$-4.73$-1.18$-1.74
Diluted EPS$-4.72$-1.18$-1.73

Fiscal year ends in Dec 22 | Currency in USD

Peer Comparison


TickerCompany
NRSNNeuroSense Therapeutics Ltd.
CNTXContext Therapeutics Inc.
ENSCEnsysce Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.